Compare Archer-Daniels-Midland Co (ADM) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Bristol-Myers Squibb Co — how do they compare? Archer-Daniels-Midland Co trades at $79.46 (market cap $38.78B), while Bristol-Myers Squibb Co trades at $63.82 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.4× Archer-Daniels-Midland Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| ADM | BMY | |
|---|---|---|
Market Cap | $38.78B | $129.94B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $65.89 |
52-Week Low | $56.00 | $42.60 |
Enterprise Value | $47.03B | $163.92B |
Dividend Yield | 2.59% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $80.49, up 5.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has declined from $101.6B in 2022 to $80.3B in 2025, but net income margin improved to 2.16% in 2025. The company raised its 2026 outlook after Q2 results, citing biofuels and nutrition strength. Valuation ratios include a P/E of 21.98 and P/S of 0.48, indicating potential undervaluation relative to earnings growth prospects.
Outlook is positive with analyst consensus price target of $88.00, though execution risks and competitive pressures remain. Investment opportunity lies in continued margin expansion and biofuel demand, while risks include volatile commodity prices and debt levels. The stock offers a dividend yield supported by 379 consecutive quarterly payments.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
